← Leaderboards
Leif W Ellisen
Massachusetts General Hospital
$14,503,955
Attributed
$17,917,118
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,524,415 · 9
By mechanism
R01$16,511,239 · 5
P50$3,033,985 · 2
K08$541,404 · 1
R21$437,787 · 1
Top collaborators
- Aditya Bardia4 shared
- Naomi Yu Ko4 shared
- Priscilla Kaliopi Brastianos2 shared
- Esther Rheinbay2 shared
- Nancy U Lin1 shared
- Kornelia Polyak1 shared
- Geoffrey I Shapiro1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jonathan L Tilly$11,512,275
- Matthew Robert Ramsey$1,794,660
- Aditya Bardia$1,099,974
- Sara Isabel Pai$12,404,338
- Naomi Yu Ko$1,392,762
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorPathway InteractionsResponseMediatingGenesIn VivoMutantCellsNeoplastic CellResistanceComplexSignal TransductionMutationRegulationPhysiologicalInsightSamplingBiochemicalSpecimenChemotherapyMalignant NeoplasmsGenomicsExhibitsGenetic
Grant awards (45)
Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer$2,607,297
P50 · FY2025 · CA
Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans$784,127
R01 · FY2025 · CA · contact PI
Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer$701,661
R01 · FY2025 · CA
Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer$559,783
R01 · FY2025 · CA · contact PI
Project 1: Incorporating antibody drug conjugates into mechanism-based combinations to target metastatic breast cancer$426,688
P50 · FY2025 · CA · contact PI
Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancer$701,408
R01 · FY2024 · CA
Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans$547,398
R01 · FY2024 · CA · contact PI
Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer$531,794
R01 · FY2024 · CA · contact PI
Landscape and characterization of promoter mutations driving triple-negative breast cancer$188,038
R21 · FY2024 · CA
Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans$702,828
R01 · FY2023 · CA · contact PI
Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer$548,587
R01 · FY2023 · CA · contact PI
Landscape and characterization of promoter mutations driving triple-negative breast cancer$249,749
R21 · FY2023 · CA
Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans$751,170
R01 · FY2022 · CA · contact PI
Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer$559,783
R01 · FY2022 · CA · contact PI
P63 Mechanisms and mediators in HNSCC$398,493
R01 · FY2021 · DE · contact PI
P63 Mechanisms and mediators in HNSCC$398,493
R01 · FY2020 · DE · contact PI
P63 Mechanisms and mediators in HNSCC$398,493
R01 · FY2019 · DE · contact PI
P63 Mechanisms and mediators in HNSCC$398,493
R01 · FY2018 · DE · contact PI
P63 Mechanisms and mediators in HNSCC$398,493
R01 · FY2017 · DE · contact PI
Function and mechanism of REDD1/mTOR signaling in metabolism and tumorigenesis$320,682
R01 · FY2017 · CA · contact PI
Function and mechanism of REDD1/mTOR signaling in metabolism and tumorigenesis$320,682
R01 · FY2016 · CA · contact PI
P63 mechanisms and mediators in HNSCC$431,669
R01 · FY2015 · DE · contact PI
Function and mechanism of REDD1/mTOR signaling in metabolism and tumorigenesis$320,682
R01 · FY2015 · CA · contact PI
P63 mechanisms and mediators in HNSCC$431,765
R01 · FY2014 · DE · contact PI
Function and mechanism of REDD1/mTOR signaling in metabolism and tumorigenesis$311,062
R01 · FY2014 · CA · contact PI
P63 mechanisms and mediators in HNSCC$414,585
R01 · FY2013 · DE · contact PI
Function and mechanism of REDD1/mTOR signaling in metabolism and tumorigenesis$320,682
R01 · FY2013 · CA · contact PI
P63 mechanisms and mediators in HNSCC$432,361
R01 · FY2012 · DE · contact PI
P63 mechanisms and mediators in HNSCC$435,320
R01 · FY2011 · DE · contact PI
Function and mechanism of REDD1 signaling to TSC1/2 and mTORC1$314,232
R01 · FY2011 · CA · contact PI
P63 mediators as therapeutic targets in HNSCC$442,500
R01 · FY2010 · DE · contact PI
Function and mechanism of REDD1 signaling to TSC1/2 and mTORC1$323,950
R01 · FY2010 · CA · contact PI
P63 mediators as therapeutic targets in HNSCC$437,474
R01 · FY2009 · DE · contact PI
Function and mechanism of REDD1 signaling to TSC1/2 and mTORC1$326,800
R01 · FY2009 · CA · contact PI
P63 mediators as therapeutic targets in HNSCC$369,240
R01 · FY2008 · DE · contact PI
Function and mechanism of REDD1 signaling to TSC1/2 and mTORC1$329,650
R01 · FY2008 · CA · contact PI
P63 mediators as therapeutic targets in HNSCC$373,347
R01 · FY2007 · DE · contact PI
Function and mechanism of REDD1 signaling to TSC1/2 and mTORC1$329,650
R01 · FY2007 · CA · contact PI
P63 mediators as therapeutic targets in HNSCC$384,498
R01 · FY2006 · DE · contact PI
P63 mediators as therapeutic targets in HNSCC$393,750
R01 · FY2005 · DE
P63 mediators as therapeutic targets in HNSCC$365,654
R01 · FY2004 · DE
TELOMERASE FUNCTIONS IN DIFFERENTIATION &TRANSFORMATION$135,351
K08 · FY2003 · CA
TELOMERASE FUNCTIONS IN DIFFERENTIATION &TRANSFORMATION$135,351
K08 · FY2002 · CA
TELOMERASE FUNCTIONS IN DIFFERENTIATION &TRANSFORMATION$135,351
K08 · FY2001 · CA
TELOMERASE FUNCTIONS IN DIFFERENTIATION &TRANSFORMATION$135,351
K08 · FY2000 · CA